Grade My Investments
HomeFree Stock Grades › TNDM

Tandem Diabetes Care, Inc. (TNDM) Stock Grade

TNDM · Healthcare

D+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.5B
P/E Ratio
Revenue Growth (YoY)
+7.9%
Net Margin
-20.2%
Return on Equity
Dividend Yield
None

About Tandem Diabetes Care, Inc.'s fundamentals

Tandem Diabetes Care is a medical device company with a market capitalization of $1.5 billion that is currently unprofitable, with a net margin of -20.2% and a reported net loss in its latest annual statement. The company is growing revenues year-over-year at 7.9%, indicating modest top-line expansion despite operating losses. With no dividend yield and negative profitability, the company is reinvesting resources into operations and growth rather than returning capital to shareholders.

Track TNDM free — no credit card required. Live grade + monthly AI report →